Grifols SA, Barcelona (GRFS) Shares Bought by Great West Life Assurance Co. Can

Great West Life Assurance Co. Can lifted its holdings in shares of Grifols SA, Barcelona (NASDAQ:GRFS) by 6.6% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 445,901 shares of the biotechnology company’s stock after purchasing an additional 27,470 shares during the quarter. Great West Life Assurance Co. Can owned about 0.07% of Grifols SA, Barcelona worth $9,718,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Advisory Services Network LLC grew its holdings in shares of Grifols SA, Barcelona by 26.2% during the 2nd quarter. Advisory Services Network LLC now owns 9,564 shares of the biotechnology company’s stock worth $202,000 after purchasing an additional 1,987 shares during the period. Dynamic Technology Lab Private Ltd purchased a new position in shares of Grifols SA, Barcelona during the 2nd quarter worth $223,000. Stevens Capital Management LP purchased a new position in shares of Grifols SA, Barcelona during the 2nd quarter worth $236,000. Advisor Group Inc. grew its holdings in shares of Grifols SA, Barcelona by 2.8% during the 2nd quarter. Advisor Group Inc. now owns 11,471 shares of the biotechnology company’s stock worth $242,000 after purchasing an additional 309 shares during the period. Finally, Stifel Financial Corp grew its holdings in shares of Grifols SA, Barcelona by 5.2% during the 2nd quarter. Stifel Financial Corp now owns 12,237 shares of the biotechnology company’s stock worth $265,000 after purchasing an additional 607 shares during the period. Institutional investors and hedge funds own 22.52% of the company’s stock.

Grifols SA, Barcelona (NASDAQ:GRFS) opened at $22.07 on Wednesday. Grifols SA, Barcelona has a 12 month low of $14.33 and a 12 month high of $24.20. The company has a current ratio of 3.17, a quick ratio of 1.39 and a debt-to-equity ratio of 1.69. The stock has a market capitalization of $15,124.53, a PE ratio of 20.51, a P/E/G ratio of 1.62 and a beta of 1.04.

Several equities analysts recently issued reports on GRFS shares. Zacks Investment Research lowered Grifols SA, Barcelona from a “buy” rating to a “hold” rating in a research note on Wednesday, October 11th. Citigroup started coverage on Grifols SA, Barcelona in a research note on Tuesday, October 31st. They set a “buy” rating on the stock. Finally, UBS lowered Grifols SA, Barcelona from an “outperform” rating to a “market perform” rating in a research note on Friday, November 24th. Two equities research analysts have rated the stock with a sell rating, three have issued a hold rating and three have assigned a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $24.00.

COPYRIGHT VIOLATION NOTICE: This report was first posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this report on another publication, it was copied illegally and reposted in violation of U.S. & international copyright and trademark laws. The legal version of this report can be read at https://ledgergazette.com/2017/12/06/grifols-sa-barcelona-grfs-shares-bought-by-great-west-life-assurance-co-can.html.

About Grifols SA, Barcelona

Grifols, SA, a specialty pharmaceutical company, develops, manufactures, and distributes biological medicines on plasma derived proteins in the United States, Canada, Spain, rest of the European Union, and internationally. The company specializes in providing infusion solutions, nutrition products, and medical devices for use in hospitals and clinics.

Institutional Ownership by Quarter for Grifols SA, Barcelona (NASDAQ:GRFS)

Receive News & Ratings for Grifols SA Barcelona Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Grifols SA Barcelona and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply